Symbols

ENOV

Enovis·NYSE

--(--)

ENOV fundamentals

ENOV Q4 2025 Earnings

Enovis (ENOV) released its earnings on Feb 26, 2026: revenue was 575.76M (YoY +2.64%), missed estimates; EPS was 0.95 (YoY -3.06%), beat estimates.

Revenue / YoY

575.76M

+2.64%

EPS / YoY

0.95

-3.06%

Report date

Feb 26, 2026

ENOV Earnings Call Summary for Q4,2025

Revenue Growth: 6% organic in 2025 (8% in Recon, 4% in P&R), driven by extremities and hip/knee implants.
Profitability: 61% gross margin (170bps up), 17.9% EBITDA margin, and $3.30 EPS (16% growth).
2026 Guidance: $2.31-2.37B revenue, 25%+ free cash flow conversion, and 50bps margin expansion.
Innovation: Arvis launch in 2026, 50%+ 510(k) clearances in 2025, and multiyear pipeline for extremities.
Execution Focus: Commercial execution, cost control, and debt reduction to 3x leverage.

Earnings

EPS

Revenue

Revenue & Expenses

ENOV has released its 2025 Q4 earnings report, with revenue of 575.76M, reflecting a YoY change of 2.64%, and net profit of -520.45M, showing a YoY change of 25.99%. The Sankey diagram below clearly presents ENOV's revenue sources and cost distribution.

Key Indicators

Enovis (ENOV) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Enovis (ENOV)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Enovis (ENOV)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Enovis (ENOV)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown